The SELECT trial is venturing into using semaglutide for patients with atherosclerotic cardiovascular disease (ASCVD) and obesity, suggesting a broader role for GLP1-RAs beyond diabetes management, extending into cardiovascular prevention [120,121]. Here, GLP1R is linked to obesity disorder.